| | | |
| | anti-CD3 | -0.07 (p = 0.87) |
| SEB | 0.43 (p = 0.30) | |
| CMV | -0.59 (p = 0.045)*** | |
| Gag p55 peptide pool | -0.40 (p = 0.17) | |
| %CD57+ | -0.69 (p = 0.0095)*** | |
| CD57+ MFI | -0.03 (p = 0.93) | |
| %CD28 | -0.38 (p = 0.19) |

| | | |
| | anti-CD3 | -0.07 (p = 0.87) |
| SEB | 0.43 (p = 0.30) | |
| CMV | -0.59 (p = 0.045)*** | |
| Gag p55 peptide pool | -0.40 (p = 0.17) | |
| %CD57+ | -0.69 (p = 0.0095)*** | |
| CD57+ MFI | -0.03 (p = 0.93) | |
| %CD28 | -0.38 (p = 0.19) |

| | | |
| | anti-CD3 | -0.07 (p = 0.87) |
| SEB | 0.43 (p = 0.30) | |
| CMV | -0.59 (p = 0.045)*** | |
| Gag p55 peptide pool | -0.40 (p = 0.17) | |
| %CD57+ | -0.69 (p = 0.0095)*** | |
| CD57+ MFI | -0.03 (p = 0.93) | |
| %CD28 | -0.38 (p = 0.19) |

| | | |
| | anti-CD3 | -0.07 (p = 0.87) |
| SEB | 0.43 (p = 0.30) | |
| CMV | -0.59 (p = 0.045)*** | |
| Gag p55 peptide pool | -0.40 (p = 0.17) | |
| %CD57+ | -0.69 (p = 0.0095)*** | |
| CD57+ MFI | -0.03 (p = 0.93) | |
| %CD28 | -0.38 (p = 0.19) |

| | | |
| | anti-CD3 | -0.07 (p = 0.87) |
| SEB | 0.43 (p = 0.30) | |
| CMV | -0.59 (p = 0.045)*** | |
| Gag p55 peptide pool | -0.40 (p = 0.17) | |
| %CD57+ | -0.69 (p = 0.0095)*** | |
| CD57+ MFI | -0.03 (p = 0.93) | |
| %CD28 | -0.38 (p = 0.19) |

| | | |
| | anti-CD3 | -0.07 (p = 0.87) |
| SEB | 0.43 (p = 0.30) | |
| CMV | -0.59 (p = 0.045)*** | |
| Gag p55 peptide pool | -0.40 (p = 0.17) | |
| %CD57+ | -0.69 (p = 0.0095)*** | |
| CD57+ MFI | -0.03 (p = 0.93) | |
| %CD28 | -0.38 (p = 0.19) |

| | | |
| | anti-CD3 | -0.07 (p = 0.87) |
| SEB | 0.43 (p = 0.30) | |
| CMV | -0.59 (p = 0.045)*** | |
| Gag p55 peptide pool | -0.40 (p = 0.17) | |
| %CD57+ | -0.69 (p = 0.0095)*** | |
| CD57+ MFI | -0.03 (p = 0.93) | |
| %CD28 | -0.38 (p = 0.19) |

| IL-2 | IL-4 | IL-6 | IL-10 | IL-13 | IFN-γ | TNF-α | LT-α | CD154 | TRANCE | |
| RA1 ( | 0 (0) | 0 (0) | 0 (0) | 7 (14) | 0 (0) | 11 (22) | 0 (0) | 6 (12) | 7 (14) | 8 (16) |
| RA2 ( | 0 (0) | 0 (0) | 0 (0) | 5 (13) | 1 (3) | 3 (8) | 0 (0) | 1 (3) | 10 (26) | 1 (3) |
| RA3 ( | 0 (0) | 0 (0) | 0 (0) | 4 (6) | 4 (6) | 4 (6) | 3 (5) | 4 (6) | 14 (22) | 3 (5) |
| Total ( | 0 (0) | 0 (0) | 0 (0) | 16 (11) | 5 (3) | 18 (12) | 3 (2) | 11 (7) | 31 (20) | 12 (8) |

| CLA | Integrin α4β7 | CCR4 | CCR9 | ||||||
| Blood | CSF | Blood | CSF | Blood | CSF | Blood | CSF | ||
| NIND | Mean | 14.2 | 11.5 | 33.0 | 17.9 | 59.8 | 41.7 | 8.0 | 5.1 |
| SD | 6.1 | 4.3 | 5.9 | 3.0 | 10.8 | 8.2 | 2.8 | 4.3 | |
| n | 10 | 10 | 4 | 4 | 5 | 5 | 8 | 8 | |
| MS | Mean | n.d. | n.d. | n.d. | n.d. | 69.6 | 48.4 | n.d. | n.d. |
| SD | 11.5 | 15.3 | |||||||

| Cell phenotype | Median MFI (range)/percentage positive (%) index | Changea | | | |
| | |||||
| Day 0 | Day 8 | ||||
| CD25 | 8.0 (2–49)/9% | 61 (6–884)/18% | 7.5 | <0.0001 | 40 |
| CD69 | 5.0 (2–43)/1.1% | 41 (5–552)/26.7% | 8 | <0.0001 | 41 |
| HLA-DR | 19 (4–130)/9% | 60 (11–238)/15% | 3 | 0.0052 | 15 |
| CD62L | 22 (8–255)/17% | 339 (7–1,040)/58% | 15 | <0.0001 | 31 |
| CD18 | 107 (9–1,026)/97.5% | 319 (53–2,040)/98.5% | 3 | 0.0085 | 21 |

| Cell phenotype | Median MFI (range)/percentage positive (%) index | Changea | | | |
| | |||||
| Day 0 | Day 8 | ||||
| CD25 | 8.0 (2–49)/9% | 61 (6–884)/18% | 7.5 | <0.0001 | 40 |
| CD69 | 5.0 (2–43)/1.1% | 41 (5–552)/26.7% | 8 | <0.0001 | 41 |
| HLA-DR | 19 (4–130)/9% | 60 (11–238)/15% | 3 | 0.0052 | 15 |
| CD62L | 22 (8–255)/17% | 339 (7–1,040)/58% | 15 | <0.0001 | 31 |
| CD18 | 107 (9–1,026)/97.5% | 319 (53–2,040)/98.5% | 3 | 0.0085 | 21 |

| Patient | Proviral load (% PBMC) | Rate of CTL lysis (per CD8+ cell per day) | %Tax expression (Tax+CD4+/CD4+) | Mean Tax expression | Fold Increase in Tax Expression (HAM÷AC) | ||
| Group 1 | AC | HBD | 0.0 | 0.220 | 0.1 | 1.3 | 2.8 |
| HT | 1.0 | 0.062 | 3.1 | ||||
| HY | 0.4 | 0.065 | 0.6 | ||||
| HAM | TAQ | 1.0 | 0.083 | 2.7 | 3.5 | ||
| TAY | 2.2 | 0.298 | 4.4 | ||||

| Patient | Proviral load (% PBMC) | Rate of CTL lysis (per CD8+ cell per day) | %Tax expression (Tax+CD4+/CD4+) | Mean Tax expression | Fold Increase in Tax Expression (HAM÷AC) | ||
| Group 1 | AC | HBD | 0.0 | 0.220 | 0.1 | 1.3 | 2.8 |
| HT | 1.0 | 0.062 | 3.1 | ||||
| HY | 0.4 | 0.065 | 0.6 | ||||
| HAM | TAQ | 1.0 | 0.083 | 2.7 | 3.5 | ||
| TAY | 2.2 | 0.298 | 4.4 | ||||

| Patient | Proviral load (% PBMC) | Rate of CTL lysis (per CD8+ cell per day) | %Tax expression (Tax+CD4+/CD4+) | Mean Tax expression | Fold Increase in Tax Expression (HAM÷AC) | ||
| Group 1 | AC | HBD | 0.0 | 0.220 | 0.1 | 1.3 | 2.8 |
| HT | 1.0 | 0.062 | 3.1 | ||||
| HY | 0.4 | 0.065 | 0.6 | ||||
| HAM | TAQ | 1.0 | 0.083 | 2.7 | 3.5 | ||
| TAY | 2.2 | 0.298 | 4.4 | ||||

| Patient | Proviral load (% PBMC) | Rate of CTL lysis (per CD8+ cell per day) | %Tax expression (Tax+CD4+/CD4+) | Mean Tax expression | Fold Increase in Tax Expression (HAM÷AC) | ||
| Group 1 | AC | HBD | 0.0 | 0.220 | 0.1 | 1.3 | 2.8 |
| HT | 1.0 | 0.062 | 3.1 | ||||
| HY | 0.4 | 0.065 | 0.6 | ||||
| HAM | TAQ | 1.0 | 0.083 | 2.7 | 3.5 | ||
| TAY | 2.2 | 0.298 | 4.4 | ||||

| Patient | Proviral load (% PBMC) | Rate of CTL lysis (per CD8+ cell per day) | %Tax expression (Tax+CD4+/CD4+) | Mean Tax expression | Fold Increase in Tax Expression (HAM÷AC) | ||
| Group 1 | AC | HBD | 0.0 | 0.220 | 0.1 | 1.3 | 2.8 |
| HT | 1.0 | 0.062 | 3.1 | ||||
| HY | 0.4 | 0.065 | 0.6 | ||||
| HAM | TAQ | 1.0 | 0.083 | 2.7 | 3.5 | ||
| TAY | 2.2 | 0.298 | 4.4 | ||||

| IFN-g, % pos | IL4, % pos | CD25, % pos | |
| CD19-Fc, 1:100 | 3.0 | 2.3 | 10.3 |
| ephrin-A4-Fc, 1:100 | 1.9 | 1.4 | 6.1 |
| CD19-Fc, 1:10 | 10.2 | 2.6 | 19.3 |
| ephrin-A4-Fc, 1:10 | 7.4 | 2.1 | 17.3 |

| IFN-g, % pos | IL4, % pos | CD25, % pos | |
| CD19-Fc, 1:100 | 3.0 | 2.3 | 10.3 |
| ephrin-A4-Fc, 1:100 | 1.9 | 1.4 | 6.1 |
| CD19-Fc, 1:10 | 10.2 | 2.6 | 19.3 |
| ephrin-A4-Fc, 1:10 | 7.4 | 2.1 | 17.3 |

| CCR9 | chemokine (C-C motif) receptor 9 | NM_031200 | +3.0 | < 0.01 |
| CCL5 | chemokine (C-C motif) ligand 5 | NM_002985 | +2.4 | < 0.01 |
| RAM2 | transcription factor RAM2 | NM_018719 | +2.2 | < 0.01 |
| LRRN3 | leucine rich repeat neuronal 3 | AL442092 | +2.1 | < 0.01 |
| GFI1 | growth factor independent 1 | NM_005263 | +1.8 | < 0.01 |
| ITGA4 | integrin, alpha 4 (CD49D) | NM_000885 | +1.7 | < 0.01 |
| CD1C | CD1C antigen, c polypeptide | NM_001765 | +1.7 | < 0.01 |

| CCR9 | chemokine (C-C motif) receptor 9 | NM_031200 | +3.0 | < 0.01 |
| CCL5 | chemokine (C-C motif) ligand 5 | NM_002985 | +2.4 | < 0.01 |
| RAM2 | transcription factor RAM2 | NM_018719 | +2.2 | < 0.01 |
| LRRN3 | leucine rich repeat neuronal 3 | AL442092 | +2.1 | < 0.01 |
| GFI1 | growth factor independent 1 | NM_005263 | +1.8 | < 0.01 |
| ITGA4 | integrin, alpha 4 (CD49D) | NM_000885 | +1.7 | < 0.01 |
| CD1C | CD1C antigen, c polypeptide | NM_001765 | +1.7 | < 0.01 |
